A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Public ClinicalTrials.gov record NCT05083481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05083481
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Interventions
- 5-Fluorouracil Drug
- ASP1570 Drug
- Bevacizumab Drug
- Carboplatin Drug
- Docetaxel Drug
- Irinotecan Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Pemetrexed Drug
- Trifluridine + Tipiracil Drug
- pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2021
- Primary completion
- Jun 29, 2026
- Completion
- Jun 29, 2026
- Last update posted
- May 4, 2026
2021 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Foundation | Fullerton | California | 92835 | — |
| California Research Institute | Los Angeles | California | 90027 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Florida Cancer Specialist & Research Institute Sarasota | Sarasota | Florida | 34232 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Kentucky Medical Center MCC-CRO | Lexington | Kentucky | 40536 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68130 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Mary Crowley Research Center | Dallas | Texas | 75230 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05083481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05083481 live on ClinicalTrials.gov.